Details for Patent: 7,919,499

Which drugs does patent 7,919,499 protect, and when does it expire?

Patent 7,919,499 protects VIVITROL and is included in one NDA.

This patent has eighteen patent family members in eleven countries.

Summary for Patent: 7,919,499

Title:	Naltrexone long acting formulations and methods of use
Abstract:	The inventions described herein arose from unexpected discoveries made during clinical trials with a long acting formulation of naltrexone. As such, the invention includes a method for treating an individual in need of naltrexone comprising the step of parenterally administering a long acting formulation comprising naltrexone and to the use of naltrexone in the manufacture of medicaments for use in such methods.
Inventor(s):	Ehrich; Elliot (Lincoln, MA)
Assignee:	Alkermes, Inc. (Waltham, MA)
Application Number:	11/083,167
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,919,499
Patent Claim Types: see list of patent claims	Use; Formulation; Dosage form;

Drugs Protected by US Patent 7,919,499

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Alkermes	VIVITROL	naltrexone	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	021897-001	Apr 13, 2006		RX	Yes	Yes						PREVENTION OF RELAPSE TO OPIOID DEPENDENCE, FOLLOWING OPIOID DETOXIFICATION
Alkermes	VIVITROL	naltrexone	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	021897-001	Apr 13, 2006		RX	Yes	Yes						TREATMENT OF ALCOHOL DEPENDENCE

International Family Members for US Patent 7,919,499

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2005239989
Canada	2563086
China	103251597
China	1946353
European Patent Office	1740120
European Patent Office	2386269